The impact of pre-transplant minimal residual disease on outcome of intensified myeloablative cord blood transplant for acute myeloid leukemia in first or second complete remission

References

• Zheng C, Zhu X, Tang B, et al. Comparative analysis of unrelated cord blood transplantation and HLA-matched sibling hematopoietic stem cell transplantation in children with high-risk or advanced acute leukemia. Ann Hematol 2015; 94: 473–480.
   PubMed Web of Science ®Google Scholar
• Takahashi S, Ooi J, Tomonari A, et al. Comparative single-institute analysis of cord blood transplantation from unrelated donors with bone marrow or peripheral blood stem-cell transplants from related donors in adult patients with hematologic malignancies after myeloablative conditioning regimen. Blood 2007; 109: 1322–1330.
   PubMed Web of Science ®Google Scholar
• Yi ES, Lee SH, Son MH, et al. Hematopoietic stem cell transplantation in children with acute leukemia: similar outcomes in recipients of umbilical cord blood versus marrow or peripheral blood stem cells from related or unrelated donors. Korean J Pediatr 2012; 55: 93–99.
   PubMedGoogle Scholar
• Liu HL, Sun ZM, Geng LQ, et al. Similar survival, but better quality of life after myeloablative transplantation using unrelated cord blood vs matched sibling donors in adults with hematologic malignancies. Bone Marrow Transplant 2014; 49: 1063–1069.
   PubMed Web of Science ®Google Scholar
• Terwijn M, van Putten WL, Kelder A, et al. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. J Clin Oncol 2013; 31: 3889–3897.
   PubMed Web of Science ®Google Scholar
• Buccisano F, Maurillo L, Del Principe MI, et al. Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. Blood 2012; 119: 332–341.
   PubMed Web of Science ®Google Scholar
• van der Velden VH, van der Sluijs-Geling A, Gibson BE, et al. Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol. Leukemia 2010; 24: 1599–1606.
   PubMed Web of Science ®Google Scholar
• Buccisano F, Maurillo L, Spagnoli A, et al. Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia. Blood 2010; 116: 2295–2303.
   PubMed Web of Science ®Google Scholar
• Bastos-Oreiro M, Perez-Corral A, Martínez-Laperche C, et al. Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute myeloid leukemia before and after allogeneic hemopoietic stem cell transplantation. Eur J Haematol 2014; 93: 239–246.
   PubMed Web of Science ®Google Scholar
• Walter RB, Gooley TA, Wood BL, et al. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. J Clin Oncol 2011; 29: 1190–1197.
   PubMed Web of Science ®Google Scholar
• Laane E, Derolf AR, Björklund E, et al. The effect of allogeneic stem cell transplantation on outcome in younger acute myeloid leukemia patients with minimal residual disease detected by flow cytometry at the end of post-remission chemotherapy. Haematologica 2006; 91: 833–836.
   PubMed Web of Science ®Google Scholar
• Vidriales MB, San-Miguel JF, Orfao A, et al. Minimal residual disease monitoring by flow cytometry. Best Pract Res Clin Haematol 2003; 16: 599–612.
   PubMed Web of Science ®Google Scholar
• Leroy H, de Botton S, Grardel-Duflos N, et al. Prognostic value of real-time quantitative PCR (RQ-PCR) in AML with t(8;21). Leukemia 2005; 19: 367–372.
   PubMed Web of Science ®Google Scholar
• Dignan FL, Clark A, Amrolia P, et al; Haemato-oncology Task Force of British Committee for Standards in Haematology; British Society for Blood and Marrow Transplantation. Diagnosis and management of acute graft-versus-host disease. Br J Haematol 2012; 158: 30–45.
   PubMed Web of Science ®Google Scholar
• Dignan FL, Amrolia P, Clark A, et al; Haemato-oncology Task Force of British Committee for Standards in Haematology; British Society for Blood and Marrow Transplantation. Diagnosis and management of chronic graft-versus-host disease. Br J Haematol 2012; 158: 46–61.
   PubMed Web of Science ®Google Scholar
• Walter RB, Buckley SA, Pagel JM, et al. Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. Blood 2013; 122: 1813–1821.
   PubMed Web of Science ®Google Scholar
• Leung W, Pui CH, Coustan-Smith E, et al. Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia. Blood 2012; 120: 468–472.
   PubMed Web of Science ®Google Scholar
• Mori T, Aisa Y, Watanabe R, et al. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for de novo acute myelogenous leukemia with a conditioning regimen of total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine. Biol Blood Marrow Transplant 2008; 14: 651–657.
   PubMed Web of Science ®Google Scholar
• Inamoto Y, Nishida T, Suzuki R, et al. Significance of additional high-dose cytarabine in combination with cyclophosphamide plus total body irradiation regimen for allogeneic stem cell transplantation. Bone Marrow Transplant 2007; 39: 25–30.
   PubMed Web of Science ®Google Scholar
• Hong M, Wu Q, Hu C, et al. Idarubicin-intensified BUCY2 regimens may lower relapse rate and improve survival in patients undergoing allo-SCT for high-risk hematological malignancies: a retrospective analysis. Bone Marrow Transplant 2012; 47: 196–202.
   PubMed Web of Science ®Google Scholar
• Zheng C, Tang B, Yao W, et al. Comparison of unrelated cord blood transplantation and HLA-matched sibling hematopoietic stem cell transplantation for patients with chronic myeloid leukemia in advanced stage. Biol Blood Marrow Transplant 2013; 19: 1708–1712.
   PubMed Web of Science ®Google Scholar
• Atsuta Y, Kanda J, Takanashi M, et al; HLA Working Group of the Japan Society for Hematopoietic Cell Transplantation. Different effects of HLA disparity on transplant outcomes after single-unit cord blood transplantation between pediatric and adult patients with leukemia. Haematologica 2013; 98: 814–822.
   PubMed Web of Science ®Google Scholar
• Eapen M, Rubinstein P, Zhang MJ, et al. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. Lancet 2007; 369: 1947–1954.
   PubMed Web of Science ®Google Scholar
• Merindol N, Charrier E, Duval M, et al. Complementary and contrasting roles of NK cells and T cells in pediatric umbilical cord blood transplantation. J Leukoc Biol 2011; 90: 49–60.
   PubMed Web of Science ®Google Scholar
• Soiffer RJ, Lerademacher J, Ho V, et al. Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood 2011; 117: 6963–6970.
   PubMed Web of Science ®Google Scholar
• Du K, Hu Y, Wu K, et al. Long-term outcomes of antithymocyte globulin in patients with hematological malignancies undergoing myeloablative allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis. Clin Transplant 2013; 27: E91–E100.
   PubMed Web of Science ®Google Scholar
• Zheng C, Luan Z, Fang J, et al. Comparison of conditioning regimens with or without antithymocyte globulin for unrelated cord blood transplantation in children with high-risk or advanced hematological malignancies. Biol Blood Marrow Transplant 2015; 21: 707–712.
   PubMed Web of Science ®Google Scholar